Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 25;12(4):321. doi: 10.1038/s41419-021-03594-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A Expression of TCLlnc1 in tumors of anaplastic large-cell lymphoma (ALCL)-anaplastic lymphoma kinase (ALK)-positive (ALK⁺ALCL, n = 9), ALCL-ALK negative (ALK⁻ALCL, n = 6), angioimmunoblastic T cell lymphoma (AITL, n = 23), and peripheral T cell lymphoma-not otherwise specified (PTCL-NOS, n = 32), as compared to RH (n = 16) by quantitative real-time polymerase chain reaction (qRT-PCR). B Correlation between TCLlnc1 expression in tumor and in serum of PTCL patients (n = 70). C Expression of TCLlnc1 in serum of RH (n = 10), ALK⁺ALCL (n = 18), ALK⁻ALCL (n = 12), AITL (n = 53), and PTCL-NOS (n = 55) in comparison with healthy volunteers (HV, n = 10). TCLlnc1 expression was quantified by qRT-PCR. D, E Progression-free survival (PFS, D) and overall survival (OS, E) of PTCL patients according to TCLlnc1 expression in serum (n = 138). F, G Univariate and multivariate analysis for PFS (F) and OS (G) in PTCL (n = 138).